M&A / Deals Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset BioSpaceMereo BioPharma's asset, dubbed alvelestat, is set to enter Phase 3 development for AATD-LD in 2027.Rare DiseaseRead full story pharminent August 12, 2026 (Last updated: August 14, 2026) BioSpace Mereo BioPharma’s asset, dubbed alvelestat, is set to enter Phase 3 development for AATD-LD in 2027. Rare Disease Read full story Post navigation Previous: Trump Executive Order Strips Seven Vaccines From Childhood Immunization RecommendationsNext: Eli Lilly Files Six Lawsuits to Combat Illegal Retatrutide Black Market Related Stories M&A / Deals Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront pharminent August 11, 2026 M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026 M&A / Deals Supernus and Indivior merge to create scaled, CNS-focused entity pharminent August 4, 2026
